Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2006

View Archived Issues

Phase I data on RC-1291, a ghrelin mimetic targeted for cancer cachexia

AEterna Zentaris report on novel peptidomimetic GnRH antagonist

Pfizer reports on weekly rhGh injection

Barr submits regulatory filings for acquisition of Pliva

Avicena studies ALS-08 combination therapies for ALS

Noopept shows therapeutic potential for Alzheimer's disease

Japanese agreement signed for Zevalin

DL-06001 and DL-06002 studied for symptoms of Parkinson's disease

Phase III study of TH-9507 for HIV-associated lipodystrophy cleared to continue

Phase Ib study investigates Reolysin/radiation therapy in advanced cancers

Novozymes acquires Delta Biotechnology

Sanctura XR reduces overactive bladder symptoms with good tolerability

DMXB-A improves neurocognition in schizophrenia patients

Phase I results encouraging with EKB-569 in advanced cancer patients

Pirfenidone pharmacokinetics assessed in rats, dogs and humans

Intraarticular steroids beneficial in hip osteoarthritis

Cook's Zilver stent approved for vascular use

MabThera approved for rheumatoid arthritis in Europe

European approval for MabThera as maintenance therapy in NHL

Pharmacokinetic profile of Huperzine A prodrug ZT-1 reported

Selective ACAT1 inhibitor shows plaque-stabilizing activity in a mouse model of atherosclerosis

New therapeutic agents for HIV infection disclosed in recent patents

Novel PPAR ligands for dermatological disorders described in recent Galderma patent

New coagulation factor Xa inhibitors prepared and tested

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...